dc.contributor.author | Myklebust, Mette Pernille | |
dc.contributor.author | Thor, Anna | |
dc.contributor.author | Rosenlund, Nina Benedikte | |
dc.contributor.author | Gjengstø, Peder | |
dc.contributor.author | Karlsdottir, Åsa | |
dc.contributor.author | Brydøy, Marianne | |
dc.contributor.author | Bercea, Bogdan Stefan | |
dc.contributor.author | Olsen, Christian | |
dc.contributor.author | Johnson, Ida | |
dc.contributor.author | Berg, Mathilde I. | |
dc.contributor.author | Langberg, Carl | |
dc.contributor.author | Andreassen, Kristine | |
dc.contributor.author | Kjellman, Anders | |
dc.contributor.author | Haugnes, Hege Sagstuen | |
dc.contributor.author | Dahl, Olav | |
dc.date.accessioned | 2022-02-10T11:37:28Z | |
dc.date.available | 2022-02-10T11:37:28Z | |
dc.date.issued | 2021-08-02 | |
dc.description.abstract | MicroRNA-371a-3p (miR371) has been suggested as a sensitive biomarker in testicular germ cell
cancer (TGCC). We aimed to compare miR371 with the classical biomarkers α-fetoprotein (AFP) and
β-human chorionic gonadotropin (hCG<sub>β</sub>). Overall, 180 patients were prospectively enrolled in the
study, with serum samples collected before and after orchiectomy. We compared the use of digital
droplet PCR (RT-ddPCR) with the quantitative PCR used by others for detection of miR371. The novel
RT-ddPCR protocol showed high performance in detection of miR371 in serum samples. In the study
cohort, miR371 was measured using RT-ddPCR. MiR371 detected CS1 of the seminoma and the nonseminoma sub-types with a sensitivity of 87% and 89%, respectively. The total sensitivity was 89%.
After orchiectomy, miR371 levels declined in 154 of 159 TGCC cases. The ratio of miR371 pre- and
post-orchiectomy was 20.5 in CS1 compared to 6.5 in systemic disease. AFP and hCG<sub>β</sub> had sensitivities
of 52% and 51% in the non-seminomas. MiR371 is a sensitive marker that performs better than the
classical markers in all sub-types and clinical stages. Especially for the seminomas CS1, the high
sensitivity of miR371 in detecting TGCC cells may have clinical implications. | en_US |
dc.identifier.citation | Myklebust, Thor, Rosenlund, Gjengstø, Karlsdottir, Brydøy, Bercea, Olsen, Johnson, Berg, Langberg, Andreassen, Kjellman, Haugnes h, Dahl. Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study. Scientific Reports. 2021 | en_US |
dc.identifier.cristinID | FRIDAID 1998452 | |
dc.identifier.doi | 10.1038/s41598-021-94812-2 | |
dc.identifier.issn | 2045-2322 | |
dc.identifier.uri | https://hdl.handle.net/10037/24002 | |
dc.language.iso | eng | en_US |
dc.publisher | Nature | en_US |
dc.relation.journal | Scientific Reports | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2021 The Author(s) | en_US |
dc.title | Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |